SCHEMBL1242490

SCHEMBL1242490

CCOC(=O)c1cc2ncsc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.60
ALDH1A1 P00352 8/20 0.43
KDM4E B2RXH2 7/20 0.43
HPGD P15428 6/20 0.43
RAB9A P51151 4/20 0.43
HSD17B10 Q99714 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 1/20 0.43
LMNA P02545 4/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
GAA P10253 2/20 0.43
NPC1 O15118 2/20 0.43
MEN1 O00255 2/20 0.43
GLA P06280 1/20 0.43
ATM Q13315 1/20 0.43
MAPK1 P28482 1/20 0.42
ALOX15 P16050 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
HTT P42858 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30112780 0.84 DAO (0.56) DAOALDH1A1KDM4EHPGDRAB9A
SCHEMBL7681873 0.83 DAO (0.66) DAOKDM4ERAB9AMAPTKMT2A
SCHEMBL21480411 0.78 DAO (0.72) DAOALDH1A1KDM4ERAB9APKM
SCHEMBL1242544 0.78 DAO (0.59) DAOALDH1A1KDM4EHPGDRAB9A
SCHEMBL2932315 0.77 RAB9A (0.49) ALDH1A1KDM4EHPGDRAB9AHSD17B10
SCHEMBL13395561 0.76 RAB9A (0.55) ALDH1A1KDM4EHPGDRAB9AHSD17B10
SCHEMBL10077323 0.76 RAB9A (0.55) ALDH1A1KDM4EHPGDRAB9AHSD17B10
SCHEMBL13308063 0.75 RAB9A (0.48) ALDH1A1KDM4EHPGDRAB9AHSD17B10
SCHEMBL13395468 0.75 KDM4E (0.49) ALDH1A1KDM4EHPGDRAB9AHSD17B10
SCHEMBL23146142 0.73 HPGD (0.50) ALDH1A1KDM4EHPGDRAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12049465-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PFIZER INC. (US) 2024-07-30 US disclosed
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-05-11 US disclosed
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-05-11 US disclosed
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-05-11 US disclosed
US-20230002386-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-01-05 US disclosed
US-20230002386-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2023-01-05 US disclosed
CN-111295387-B Heteroaryl amide compound, preparation method thereof, medicinal composition and application thereof 应世生物科技(南京)有限公司 2022-12-06 CN disclosed
US-11472805-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PFIZER, INC. (US) 2022-10-18 US disclosed
EP-3766885-B1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER (US) 2022-05-25 EP disclosed
EP-3766885-B1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER (US) 2022-05-25 EP disclosed
EP-3310784-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Pfizer Inc (US) 2018-04-25 EP disclosed
WO-2016203347-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2016-12-22 WO disclosed
WO-2016203347-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PFIZER INC. (US) 2016-12-22 WO disclosed
US-7884124-B2 such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions SEPRACOR INC. (US) 2011-02-08 US disclosed
US-7884124-B2 such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions SEPRACOR INC. (US) 2011-02-08 US disclosed
CN-101511832-A Fused heterocyclic inhibitors of D-amino acid oxidase SEPRACOR INC (US) 2009-08-19 CN disclosed
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase SEPRACOR INC. (US) 2008-03-06 US disclosed
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase SEPRACOR INC. (US) 2008-03-06 US disclosed
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-01-03 US disclosed
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058395-A1 Fused heterocyclic inhibitors of D-amino acid oxidase DAO, DDO, AOX1 DAO 1/4885ALDH1A1 866/4885KDM4E 2644/4885
US-12049465-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PDE3B, PDE3A, PDE5A DAO 901/4885ALDH1A1 972/4885KDM4E 1433/4885
US-20230146535-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE5A DAO 901/4885ALDH1A1 972/4885KDM4E 1433/4885
US-11472805-B2 Tricyclic compounds and their use as phosphodiesterase inhibitors PDE3B, PDE3A, PDE5A DAO 901/4885ALDH1A1 972/4885KDM4E 1433/4885
US-20080004327-A1 FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE DAO, DDO, AOX1 DAO 1/4885ALDH1A1 622/4885KDM4E 2046/4885
US-20230002386-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE5A DAO 901/4885ALDH1A1 972/4885KDM4E 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.